Review Article

Palliative Medicine: A Pharmacological Perspective

Dr. Virendra Kushwaha*, Dr. Pooja Agrawal, Dr. BK Shoraisham, Dr. Anuj Kumar, Dr. Rishabh Gupta, Dr. Shekhar Tripathi, Dr. Shweta Pandey
Pharmacology Department GSVM, Medical College, Kanpur, UP, India.
***Corresponding author's E-mail:** vkushwaha1970@gmail.com

Received: 06-03-2026; **Revised:** 20-05-2026; **Accepted:** 28-05-2026; **Published online:** 20-06-2026.

ABSTRACT

Background: Palliative medicine has emerged as an indispensable discipline within modern healthcare, responding to the growing burden of chronic, progressive, and life-limiting diseases worldwide. Despite advances in medical science that have improved survival in conditions such as cancer, cardiovascular diseases, neurological disorders, HIV/AIDS, and chronic organ failure, prolonged survival is frequently accompanied by persistent symptom burden, psychosocial distress, functional dependence, and reduced quality of life.

Objectives: This review critically examines the principles, historical evolution, policy framework, community-based models, and pharmacological strategies of palliative medicine, with particular emphasis on the Indian context.

Methods: A narrative review of published literature, international guidelines, and national policy documents was conducted. Relevant sources including World Health Organization guidelines, Indian national health policies, and peer-reviewed journals were synthesized.

Results: Palliative medicine adopts a holistic, person-centred approach integrating physical, psychological, social, and spiritual dimensions of care. Pharmacotherapy — including rational opioid prescribing, antiemetics, bronchodilators, anxiolytics, antidepressants, and antipsychotics — forms the backbone of symptom control. In India, frameworks such as the National Programme for Palliative Care and regulatory reforms under the Narcotic Drugs and Psychotropic Substances Act have improved access to essential medicines.

Conclusion: Integration of palliative care across all levels of healthcare is essential for humane, patient-centred, and ethically sound medical practice. Rational pharmacotherapy, multidisciplinary teamwork, and supportive health policy are the pillars of effective palliative medicine.

Keywords: Palliative medicine, pharmacotherapy, opioid analgesia, symptom management, WHO analgesic ladder, palliative care India, end-of-life care, Visual Analog Scale (VAS).

1. Introduction

Palliative medicine has emerged as a vital and indispensable discipline within modern healthcare systems, responding to the growing burden of chronic, progressive, and life-limiting diseases worldwide.[1–3] Advances in medical science have significantly improved survival in conditions such as cancer, cardiovascular diseases, neurological disorders, HIV/AIDS, and chronic organ failure; however, prolonged survival is often accompanied by persistent symptom burden, psychosocial distress, functional dependence, and reduced quality of life.[2,6] Palliative medicine addresses this gap by shifting the focus from disease-centred treatment to person-centred care.

Traditional medical practice has emphasized diagnosis, cure, and prolongation of life. While these objectives remain fundamental, they frequently fail to address the multidimensional suffering experienced by patients with advanced illness. Pain, breathlessness, fatigue, nausea, anxiety, depression, social isolation, fear of death, and spiritual distress commonly coexist, giving rise to the concept of "total pain".[4,5] Palliative medicine recognizes this complexity and adopts a holistic approach integrating physical, psychological, social, and spiritual dimensions of care.

Contrary to the misconception that palliative care is limited to terminal stages, contemporary palliative medicine advocates early integration along the disease trajectory and provision alongside curative or disease-modifying therapies.[1–3] Early palliative care improves symptom control, enhances patient and family satisfaction, facilitates informed decision making, and reduces avoidable hospital admissions.[2,7] Thus, palliative care represents a continuum of care rather than a late-stage intervention.

From a pharmacological perspective, palliative medicine is fundamentally dependent on rational drug therapy. Pharmacological interventions form the backbone of symptom control for pain, dyspnoea, nausea, anxiety, depression, delirium, insomnia, and terminal secretions.[8–10] Effective pharmacotherapy requires careful consideration of altered pharmacokinetics and pharmacodynamics due to advanced illness, organ dysfunction, age-related physiological changes, and polypharmacy.[5,9]

Pain management remains a cornerstone of palliative pharmacology.[8,9] The World Health Organization (WHO) analgesic ladder provides a globally accepted framework for cancer pain management and has significantly improved access to effective analgesia.[8] Beyond pain relief, modern palliative pharmacology emphasizes dose titration, appropriate route selection, opioid rotation, prevention and management of adverse drug reactions, ethical opioid

use, and deprescribing of non-beneficial medications to reduce treatment burden .[5,9,10]

At the public health level, palliative care is recognized as an essential component of universal health coverage. The WHO advocates integration of palliative care into national health systems through supportive policies, workforce training, and access to essential medicines. [1,2]In India, initiatives such as the National Programme for Palliative Care (NPPC) and the Indian Association of Palliative Care (IAPC), along with community-based models like the Kerala Neighbourhood Network in Palliative Care, demonstrate feasibility, sustainability, and cultural acceptability. [11,12].This review critically examines the principles, historical evolution, policy framework, community-based models, and pharmacological strategies of palliative medicine, with emphasis on the Indian context.

2. Definition of Palliative Care

According to the World Health Organization, palliative care is an approach that improves the quality of life of patients and their families facing problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification, impeccable assessment, and treatment of pain and other problems — physical, psychosocial, and spiritual .[1,2]

According to the Indian Association of Palliative Care (IAPC), palliative care is defined as the active total care of patients and their families, aimed at improving quality of life through prevention and relief of suffering by early identification, assessment, and treatment of pain and other physical, psychological, social, and spiritual problems. [11] Palliative care uses interventions that are affordable, culturally appropriate, and socially acceptable, addressing symptoms such as pain, breathlessness, nausea, fatigue, anxiety, depression, and insomnia.

3. Historical Development of Palliative Care

The roots of palliative care can be traced to ancient civilizations where compassion for the sick and dying formed an integral part of medical practice. Traditional systems such as Ayurveda emphasized holistic care, balance, and relief of suffering. Religious and charitable institutions historically provided hospice-like services to the terminally ill.

Modern palliative care originated in 19th century Europe and gained momentum through the hospice movement. Dame Cicely Saunders, regarded as the founder of modern palliative care, established St. Christopher's Hospice in London in 1967 and introduced the concept of "total pain," integrating physical, psychological, social, and spiritual suffering into patient care. [4] Her work laid the foundation for palliative medicine as a scientific and compassionate discipline.

The World Health Organization formally recognized palliative care in 1986 by publishing Cancer Pain Relief, and in 2002 issued a revised definition emphasizing its applicability beyond cancer to all life-limiting conditions. [1,8] Since then, palliative care has been increasingly recognized as an essential component of universal health coverage globally.

4. Estimating Palliative Care Need

Estimation of palliative care need is essential for timely referral and appropriate care planning. Assessment is based on disease stage and prognosis, symptom burden, functional status, psychological distress, social and spiritual concerns, caregiver burden, and frequency of hospital admissions. Tools such as performance status scales (e.g., Karnofsky Performance Scale, Eastern Cooperative Oncology Group scale), symptom assessment scales (e.g., Edmonton Symptom Assessment System), and prognostic indicators assist in identifying patients who would benefit from palliative interventions.

5. Cardinal Concepts and Holistic Care

Palliative medicine is grounded in respect for patient dignity, acceptance of death as a natural process, and patient- and family-centered care. Holistic care addresses physical, psychological, social, spiritual, and cultural dimensions of health. This approach improves quality of life, reduces suffering, enhances satisfaction, and strengthens patient–family–healthcare relationships.

The concept of "total pain," introduced by Dame Cicely Saunders, remains central to palliative practice .[4,5] It acknowledges that suffering in advanced illness extends beyond the physical and encompasses psychological fear, social isolation, existential distress, and spiritual anguish. Addressing total pain requires a coordinated, multidisciplinary response rather than pharmacological intervention alone.

6. Key Principles of Palliative Medicine

The following core principles guide palliative medicine practice [1–3,11] :

- The unit of care includes both the patient and the family.
- Symptoms should be routinely assessed using standardized, validated tools.
- Medical decisions must respect patient autonomy, informed consent, and ethical practice.
- Palliative care is delivered through interdisciplinary teamwork.
- Continuity of care is ensured across hospital, home, and community settings.
- Dying is recognized as a normal part of life; palliative care neither hastens nor postpones death .[1]
- Quality of life is prioritized over disease-focused outcomes.
- Bereavement support for families and well-being of healthcare workers are integral components.

7. Goals of Palliative Medicine

The primary goals of palliative medicine include relief from pain and other distressing symptoms, enhancement of quality of life, and provision of comprehensive support to both patients and their families. [1,2,11] Palliative care affirms life while recognizing death as a natural process and neither hastens nor postpones death. [1]

Additional goals encompass psychological and emotional support, social assistance, spiritual and existential care, advance care planning, end-of-life care, and bereavement support for family members. In the pharmacological context, optimal goal achievement depends on rational, individualized drug therapy that is regularly reassessed and adjusted in response to the patient's evolving clinical condition.

8. Role of the World Health Organization

The World Health Organization formally recognized palliative care in 1986 and emphasized its integration into national health systems. [1–3,17] The WHO advocates early incorporation of palliative care, equitable access to essential medicines — particularly opioids for pain relief — and a multidisciplinary team approach. According to the WHO, palliative care improves quality of life, supports patients to live as actively as possible, and provides support to families during illness and bereavement. [1–3]

The WHO analgesic ladder, first published in 1986, remains the global standard for cancer pain management. [8] It is a three-step framework: Step 1 employs non-opioid analgesics (e.g., paracetamol, NSAIDs) for mild pain; Step 2 adds weak opioids (e.g., codeine, tramadol) for mild-to-moderate pain; and Step 3 involves strong opioids (e.g., morphine, oxycodone, fentanyl) for moderate-to-severe pain. Adjuvant drugs are used at all steps, particularly for neuropathic and bone pain. This structured, evidence-based approach has significantly reduced unnecessary suffering across the world. [8,9]

9. Development of Palliative Care in India

Organized palliative care in India began in the 1980s. [3,11] The Indian Association of Palliative Care was established in 1994 to promote education, research, and service development. [3] Kerala emerged as a global leader with its community-based palliative care model, integrating services into primary healthcare and emphasizing community participation. The Government of India launched the National Programme for Palliative Care to improve access to services and essential medications nationwide. [12]

9.1 Kerala Model and Neighbourhood Network in Palliative Care (NNPC)

The Kerala model emphasizes social responsibility and community ownership of care. [18,19] The Neighbourhood Network in Palliative Care (NNPC) involves trained healthcare professionals, community volunteers, local self-government bodies, NGOs, and charitable organizations. This model addresses physical, psychological, and social needs, reduces hospital burden, improves access to pain relief, and is cost-effective, culturally acceptable, and sustainable. It has been recognized internationally as a replicable model for low- and middle-income countries.

9.2 Maharashtra State Palliative Care Policy

Maharashtra has developed a state-level palliative care policy focusing on institutional and home-based services. The policy integrates palliative care into tertiary hospitals, district hospitals, medical colleges, and cancer centres. It emphasizes training of healthcare professionals, improves opioid availability, and promotes collaboration with NGOs and the private sector.

10. Multidisciplinary Team Approach

Palliative care is delivered by a multidisciplinary team comprising doctors, nurses, pharmacists, social workers, psychologists, spiritual care providers, and trained volunteers. From a pharmacological viewpoint, pharmacists play a crucial role in optimizing drug therapy, preventing drug–drug interactions, ensuring rational opioid use, managing adverse effects, and educating patients and caregivers.

11. Scope of Palliative Medicine

Palliative care can be provided in hospitals, homes, and community settings and is applicable at all stages of illness. It is integrated into oncology, critical care, geriatrics, neurology, cardiology, HIV/AIDS care, and chronic disease management. Palliative medicine is now recognized as a medical specialty in many countries and as an essential component of universal health coverage.

12. Illness Trajectories and Stages

Illness trajectory describes the pattern of disease progression over time. Cancer typically shows a stable phase followed by gradual decline and rapid deterioration near death. Organ failure (e.g., heart failure, chronic renal disease) is characterized by chronic illness with acute exacerbations and the possibility of sudden death, while frailty and dementia show slow, progressive decline. Stages include early, chronic, advanced, and end-of-life phases, each requiring tailored palliative interventions.

Understanding illness trajectories is essential for anticipatory prescribing, advance care planning, and timely referral to specialist palliative services. Recognition of the dying phase — typically the last few days of life — guides transition to comfort-focused care and appropriate medication review.

13. Palliative Procedures

Palliative procedures are interventions aimed at symptom relief rather than cure. Examples include paracentesis for the relief of symptomatic ascites, pleural drainage (thoracentesis) for breathlessness due to pleural effusion, nerve blocks and neurolytic procedures for refractory pain, and stenting for malignant obstruction of hollow viscera. These procedures significantly improve comfort and quality

of life in advanced illness and are an important adjunct to pharmacological management. [97–99]

14. Pharmacological Aspects in Palliative Medicine

Pharmacotherapy is central to palliative care. [5,8–10] In India, opioid availability and prescribing for palliative care are governed by the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 and subsequent amendments. The NDPS (Amendment) Act, 2014 simplified licensing for medical institutions by introducing the concept of Essential Narcotic Drugs (ENDs) and permitting state governments to allow government hospitals to procure opioids without separate licenses, thereby improving morphine availability for palliative use. [21,22] The NDPS (Amendment) Act, 2021 further clarified legislative provisions and strengthened regulatory consistency to support legitimate medical use of opioids, including in palliative care settings. [21,22]

The following sections detail pharmacological management of the major symptom domains in palliative medicine, beginning with pain — the most clinically significant and extensively studied symptom.

14.1 Pain Management

Pain is the most extensively studied and clinically significant symptom in palliative medicine. [9,85] It is defined by the International Association for the Study of Pain (IASP) as an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage [85]. In palliative medicine, pain is best understood through the concept of "total pain," which encompasses physical, psychological, social, and spiritual dimensions. [86,87] This multidimensional nature necessitates a holistic approach to management. [88]

Pain can be broadly classified into nociceptive and neuropathic types. [89] Nociceptive pain arises from tissue injury, whereas neuropathic pain results from damage to or dysfunction of the somatosensory nervous system. [90] The physiological process involves transduction, transmission, modulation, and perception. [91,92] Peripheral and central sensitization contribute to chronic pain states, resulting in hyperalgesia and allodynia. [93]

Cancer-related pain syndromes include nociceptive pain due to tumor infiltration, visceral pain from organ involvement, and neuropathic pain resulting from nerve injury or treatment-related toxicity. [94,95] .Malignant bone pain is a common and severe form, caused by tumor-induced osteolysis and inflammatory processes. [96,97] Management involves pharmacological therapy along with radiotherapy and surgical interventions when required. [98] Mirels' scoring system is used to assess fracture risk in patients with long-bone metastases. [99]

Pain assessment relies on validated tools such as the Visual Analog Scale (VAS) and Numeric Rating Scale (NRS), along with comprehensive evaluation of functional and psychosocial aspects. [100,101] Imaging studies may be required for diagnosis and treatment planning. [102]

The WHO analgesic ladder provides a structured approach to cancer pain management. [8] Step 1 uses non-opioid analgesics (paracetamol, NSAIDs) for mild pain. Step 2 adds weak opioids such as codeine or tramadol for mild-to-moderate pain. Step 3 employs strong opioids — principally oral morphine — for moderate-to-severe pain. Adjuvant therapies are incorporated at all steps, particularly for neuropathic pain, where antidepressants (e.g., amitriptyline, duloxetine) and anticonvulsants (e.g., gabapentin, pregabalin) are effective. [9,89] Breakthrough pain is managed with rapid-acting opioid formulations, while pain crises require urgent escalation of therapy. [89]

Nonsteroidal anti-inflammatory drugs (NSAIDs) — including ibuprofen, diclofenac, and naproxen — play a crucial role in mild-to-moderate pain, particularly inflammatory and bone pain conditions. [100,102] They act through inhibition of cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. [101] While valuable as opioid-sparing agents, NSAIDs require cautious use due to gastrointestinal, renal, and cardiovascular adverse effects, particularly in frail and elderly patients. [102,103]

14.2 Nausea and Vomiting

Nausea and vomiting are complex, multifactorial symptoms that arise from the integration of peripheral and central stimuli within the central nervous system. [23] The physiological basis of emesis involves a coordinated reflex mediated by a central pattern generator in the medulla oblongata (previously termed the "vomiting centre" in older literature), which receives afferent inputs from the chemoreceptor trigger zone (CTZ), the gastrointestinal tract via vagal afferents, the vestibular apparatus, and higher cortical centres. [24] The chemoreceptor trigger zone, situated in the area postrema and lacking a blood–brain barrier, is particularly sensitive to circulating toxins, drugs, and metabolic disturbances. [25]

The emetic pathway is initiated when peripheral stimuli, such as chemotherapy-induced mucosal injury, trigger the release of serotonin from enterochromaffin cells in the gastrointestinal tract, activating 5-HT_3 receptors and vagal afferents .[26] These signals are transmitted to the central pattern generator, resulting in a coordinated motor response leading to vomiting.[27]Neurotransmitters such as dopamine, serotonin, histamine, acetylcholine, and substance P play key roles at different anatomical sites, forming the basis for receptor-targeted antiemetic therapy.[28]

Antiemetic drugs are classified based on their receptor action and site of activity. [29]Dopamine antagonists such as metoclopramide and domperidone exert their effects primarily at the chemoreceptor trigger zone, [30] while serotonin (5-HT_3) antagonists such as ondansetron act on both central and peripheral receptors. [31] Neurokinin-1 (NK1) receptor antagonists such as aprepitant inhibit substance P-mediated pathways and are especially useful in delayed chemotherapy-induced emesis. [32] Antihistamines

(e.g., cyclizine, promethazine) and anticholinergics are more effective in vestibular-mediated nausea. [33]

Prokinetic agents represent an important therapeutic class, particularly in patients with gastric stasis, which is common in advanced illness. [34] Metoclopramide enhances gastric emptying through dopamine antagonism and serotonergic mechanisms.[35] The management of chemotherapy- and radiotherapy-induced nausea and vomiting illustrates the value of combining agents acting at different receptor sites.[36] Highly emetogenic regimens typically require a combination of a 5-HT_3 antagonist, dexamethasone, and an NK1 receptor antagonist, [37] while moderate-risk regimens may be managed with fewer agents. [38] Refractory nausea and vomiting may benefit from additional pharmacological strategies including low-dose olanzapine or cannabinoids.[39,40]

14.3 Respiratory Symptoms

Respiratory symptoms, particularly dyspnoea, are highly distressing and multifactorial in origin. [56,57] Opioids, especially morphine, are the cornerstone of dyspnoea management due to their central action in reducing the perception of breathlessness. [58,59] Alternatives such as fentanyl may be considered in patients with renal impairment to avoid accumulation of active metabolites . [60] Oxygen therapy is indicated primarily in hypoxemic patients and does not reliably relieve dyspnoea in non-hypoxemic individuals. [61]

In obstructive airway disease, bronchodilators such as salbutamol (short-acting β_2 agonist), formoterol (long-acting β_2 agonist), and ipratropium bromide (anticholinergic) are useful. [62,63] Systemic corticosteroids such as dexamethasone or prednisolone are beneficial in airway inflammation, lymphangitic carcinomatosis, or superior vena cava obstruction. [64,65]

Benzodiazepines, including lorazepam and midazolam, are used to relieve anxiety associated with dyspnoea. [66] For cough, antitussives such as codeine and dextromethorphan are commonly employed. [67] Excessive respiratory secretions in the dying patient (colloquially referred to as the "death rattle") are managed using anticholinergic agents such as glycopyrrolate, hyoscine butyl bromide, or scopolamine.[68,69] These approaches are consistent with palliative care principles focusing on symptom relief and patient comfort. [70]

14.4 Cardiovascular Symptoms

In advanced illness, cardiovascular symptoms such as edema, heart failure, and thromboembolism are common and require a symptom-oriented approach rather than disease-modifying strategies. [41,42] Loop diuretics such as furosemide are the mainstay for rapid relief of fluid overload, [43] while aldosterone antagonists like spironolactone are particularly beneficial in managing ascites related to hepatic or cardiac disease. [44] In selected cases, thiazide diuretics (e.g., hydrochlorothiazide) may be added for a synergistic diuretic effect. [45]

Thromboembolic complications, especially in malignancy-associated coagulopathy, are treated with low molecular weight heparins such as enoxaparin or dalteparin, which are preferred due to their predictable pharmacokinetics and ease of subcutaneous administration. [46,47] Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and edoxaban are increasingly used in appropriate patients. [48,49]

Deprescribing of non-beneficial preventive medications is an essential principle in palliative care. Long-term agents such as statins, antihypertensives, and antiplatelet drugs may be discontinued when they do not contribute to immediate symptomatic benefit and impose a pill burden without meaningful quality-of-life gain. [50–52] This approach aligns with palliative care goals of improving quality of life and minimizing drug burden.[53,54] Individualized clinical judgment, shared decision making with the patient and family, and regular medication review are essential to balance risks and benefits in end-of-life care . [55]

14.5 Neuropsychiatric Symptoms

Central nervous system manifestations — including anxiety, depression, delirium, and terminal restlessness — require individualized assessment and management. [71,72] Benzodiazepines such as lorazepam, diazepam, and midazolam are used for anxiety, agitation, and, when appropriate, palliative sedation. [73,74]

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) such as sertraline, fluoxetine, and escitalopram, are used for depression. [75] Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), may be preferred when insomnia or anorexia coexist, given its sedating and appetite-stimulating properties. [76]

For delirium, antipsychotics are first-line pharmacological therapy, with haloperidol remaining the drug of choice due to its established efficacy and available parenteral formulation. [77,78] Atypical antipsychotics including olanzapine, quetiapine, and risperidone are considered when extrapyramidal side effects are a concern. [79]

Terminal restlessness and refractory symptoms may necessitate palliative sedation, typically using subcutaneous or intravenous midazolam, with or without adjuncts such as phenobarbital or propofol in refractory cases. [70,80] This approach is guided by established ethical principles — proportionality, patient consent or best-interests determination, and multidisciplinary consensus — and by clinical guidelines in end-of-life care. [80,81] Ongoing assessment and multidisciplinary involvement are essential to optimize symptom control and patient comfort. [82,83]

14.6 Deprescribing and Medication Review in Palliative Care

Deprescribing — the planned, supervised reduction or cessation of medications that are no longer beneficial or are potentially harmful — is a core principle of palliative pharmacotherapy. [50–52] In advanced illness, patients often carry a high medication burden accumulated over years of

chronic disease management. Many of these medications (e.g., statins, bisphosphonates, vitamins, preventive antihypertensives) lose their benefit-to-risk ratio as the patient approaches the end of life.

A systematic medication review at each clinical encounter should evaluate necessity, appropriateness, and patient or family preferences. Minimizing polypharmacy reduces adverse drug interactions, tablet burden, cost, and caregiver workload, thereby improving quality of life and adherence to genuinely beneficial therapies. Selecting appropriate routes of administration — for example, transitioning to subcutaneous or transdermal delivery when the oral route is lost — is equally important in end-of-life care.

15. Health Policy and Programs in Palliative Medicine

Health policies provide a framework for planning and delivering palliative care, while programs ensure implementation.[2,12,16] Regulations support availability of essential medicines, standardization of care, and quality assurance. The ultimate aim is universal access to palliative care services.

Health programs operationalize policy goals through workforce training, service delivery models, financing mechanisms, and monitoring systems. The National Programme for Palliative Care (NPPC) in India focuses on capacity building of healthcare professionals, development of palliative care units in district hospitals and medical colleges, promotion of home-based care, and collaboration with non-governmental and community organizations. [12] Training of doctors, nurses, pharmacists, and community health workers is emphasized to address manpower shortages.

Financing and sustainability are critical components of palliative care programs. Policies advocate inclusion of palliative care services within universal health coverage and publicly funded insurance schemes to reduce out-of-pocket expenditure and improve equity. Community participation, public–private partnerships, and integration with local self-government institutions further enhance the reach and sustainability of services.

16. Integration of Symptom Management

A key principle in palliative medicine is the integration of symptom management rather than treating symptoms in isolation. [104,105] Symptoms often coexist and influence each other; for example, pain may exacerbate dyspnoea and anxiety, while nausea may be worsened by opioid therapy. [106,107] Therefore, management strategies must be individualized, dynamic, and multidisciplinary. [108,109]

Regular reassessment and adjustment of therapy are essential to ensure optimal symptom control and improved quality of life. [110,111] This holistic approach incorporates physical, psychological, social, and spiritual domains of care. [112] Effective communication and coordinated teamwork among healthcare providers further enhance patient-centred outcomes.

17. Challenges and Future Directions

Despite advances in palliative medicine, significant challenges remain, particularly in low- and middle-income countries. [7,14,18] Key barriers include shortage of trained palliative care professionals, limited public and professional awareness, inadequate infrastructure and specialist services in rural areas, rural–urban disparities in access, and regulatory barriers to opioid prescribing and availability.

Future directions include deeper integration of palliative care with primary healthcare, expansion of community-based models inspired by the Kerala NNPC, strengthening undergraduate and postgraduate training programs, improved policy support for opioid access and prescribing reforms, investment in palliative care research particularly in the Indian context, and increased public awareness campaigns. Digital health tools and telemedicine offer emerging opportunities to extend palliative care into underserved communities.

18. Discussion

This review highlights that palliative medicine is not merely a supportive adjunct but an essential discipline that addresses the holistic needs of patients with life-limiting illness from diagnosis to death. The pharmacological framework presented — from the WHO analgesic ladder for pain to receptor-targeted antiemetics, opioids for dyspnea, and rational neuropsychiatric pharmacotherapy — underscores the breadth and complexity of palliative pharmacology.

A central challenge across all symptom domains is the altered pharmacokinetics and pharmacodynamics in patients with advanced illness, organ dysfunction, cachexia, and polypharmacy. Drug doses and routes must be regularly reviewed and individualized. Emerging evidence supports the earlier integration of palliative care alongside oncological and other disease-modifying treatments, with demonstrated improvements in quality of life, patient satisfaction, and even survival in some populations. [13]

In the Indian context, the gap between palliative care need and provision remains wide. Regulatory reforms under the NDPS Act represent important progress, but implementation challenges — including reluctance among prescribers due to fear of regulatory action — continue to limit opioid access for patients who need it most. [21,22] Community-based models such as the Kerala NNPC offer scalable solutions that harness social capital and local resources alongside medical expertise. [18,19]

Future research priorities should include development of culturally validated symptom assessment tools for Indian populations, robust pharmacoeconomic analyses of palliative interventions in low-resource settings, evaluation of community-based models at scale, and clinical trials of pharmacological strategies for refractory symptoms in the Indian palliative care setting.

19. Conclusion

Palliative medicine is an essential component of modern healthcare, focusing on quality of life, ethical practice, and compassionate care. It addresses multidimensional suffering from the point of diagnosis through to end of life, and continues to support families through bereavement. From a pharmacological perspective, rational drug therapy is fundamental to effective symptom control, patient safety, and preservation of dignity.

Integration of palliative care across all levels of healthcare — primary, secondary, and tertiary — is crucial for humane, patient-centred, and ethically sound medical practice. The pharmacist, alongside physicians, nurses, and allied health professionals, plays an indispensable role in ensuring safe, effective, and person-centred pharmacotherapy. Strengthening policy, education, research, and community engagement remains the path forward for palliative medicine in India and globally.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. World Health Organization. WHO Definition of Palliative Care. Geneva: World Health Organization; 2002.
2. World Health Organization. Integrating Palliative Care and Symptom Relief into Primary Health Care. Geneva: WHO; 2018.
3. Sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative care: The World Health Organization's global perspective. J Pain Symptom Manage. 2002;24(2):91–96.
4. Saunders C. The philosophy of terminal care. Ann Acad Med Singapore. 1987;16(1):151–154.
5. Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford Textbook of Palliative Medicine. 4th ed. Oxford: Oxford University Press; 2010.
6. Lynn J, Adamson DM. Living Well at the End of Life. Santa Monica: RAND Health; 2003.
7. Smith S, Brick A, O'Hara S, Normand C. Evidence on the cost and cost-effectiveness of palliative care. Palliat Med. 2014;28(2):130–150.
8. World Health Organization. Cancer Pain Relief. Geneva: WHO; 1986.
9. Twycross R, Wilcock A, Howard P. Palliative Care Formulary. 6th ed. Nottingham: Palliativedrugs.com Ltd; 2017.
10. Meier DE, Brawley OW. Palliative care and the quality of life. J Clin Oncol. 2011;29(20):2750–2752.
11. Indian Association of Palliative Care. IAPC Definition and Position Statement. 2012.
12. Ministry of Health and Family Welfare, Government of India. National Programme for Palliative Care. 2012.
13. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–742.
14. Connor SR, Bermedo MC, editors. Global Atlas of Palliative Care at the End of Life. London: Worldwide Palliative Care Alliance; 2014.
15. Bruera E, Higginson IJ, von Gunten CF, Morita T, editors. Textbook of Palliative Medicine and Supportive Care. 3rd ed. Boca Raton: CRC Press; 2021.
16. Stjernswärd J, Foley KM, Ferris FD. The public health strategy for palliative care. J Pain Symptom Manage. 2007;33(5):486–493.
17. World Health Organization. Strengthening of Palliative Care as a Component of Comprehensive Care Throughout the Life Course. Geneva: WHO; 2014.
18. Kumar SK. Kerala, India: a regional community-based palliative care model. J Pain Symptom Manage. 2007;33(5):623–627.
19. Sallnow L, Kumar S, Kellehear A, editors. International Perspectives on Public Health and Palliative Care. Abingdon: Routledge; 2012.
20. Paleri A, Numpeli M. The evolution of palliative care programs in north Kerala. Indian J Palliat Care. 2005;11(1):15–18.
21. Ministry of Finance, Government of India. The Narcotic Drugs and Psychotropic Substances (Amendment) Act, 2014. New Delhi; 2014.
22. Ministry of Finance, Government of India. The Narcotic Drugs and Psychotropic Substances (Amendment) Act, 2021. New Delhi; 2021.
23. Andrews PLR, Davis CJ. The physiology of emesis induced by anti-cancer therapy. In: Reynolds DJM, Andrews PLR, Davis CJ, editors. Serotonin and the Scientific Basis of Anti-emetic Therapy. Oxford: Oxford Clinical Communications; 1995.
24. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111(Suppl 8A):106S–112S.
25. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953;5(2):193–230.
26. Minami M, Endo T, Hirafuji M, et al. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther. 2003;99(2):149–165.
27. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014;722:172–179.
28. Peroutka SJ, Synder SH. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982;1(8273):658–659.
29. Darmani NA, Ray AP. Evidence for a re-evaluation of the neurotransmitter basis of emesis. Eur J Pharmacol. 2009;617(1–3):1–16.
30. Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379–390.
31. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT_3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684(1–3):1–18.
32. Herrstedt J, Roila F, Warr D, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277–288.
33. Wood GJ, Shega JW, Lynch B, Von Roenn JH. Management of intractable nausea and vomiting in patients at the end of life. JAMA. 2007;298(10):1196–1207.
34. Bruera E, Belzile M, Neumann CM, et al. Twice-daily versus once-daily metoclopramide in the treatment of nausea in patients with advanced cancer. J Pain Symptom Manage. 2000;19(6):427–432.
35. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Metoclopramide: a updated review of its pharmacology and clinical application. Drugs. 1988;36(5):477–506.

36. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356–1367.

37. MASCC/ESMO Antiemetic Guidelines 2019. Available at: https://www.mascc.org/antiemetic-guidelines.

38. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–2797.

39. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for chemotherapy-induced nausea and vomiting. J Support Oncol. 2011;9(5):188–195.

40. Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015;(11):CD009464.

41. Johnson MJ, Oxberry SG, Cleland JG. Palliative therapy in heart failure. Curr Treat Options Cardiovasc Med. 2012;14(4):361–372.

42. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol. 2009;54(5):386–396.

43. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.

44. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites. Hepatology. 1996;23(1):164–176.

45. Ellison DH. The physiologic basis of diuretic synergism. Ann Intern Med. 1991;114(10):886–894.

46. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism in cancer patients. J Clin Oncol. 2007;25(34):5490–5505.

47. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153.

48. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607.

49. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624.

50. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834.

51. Holmes HM, Todd A. Evidence-based deprescribing. Clin Geriatr Med. 2017;33(2):165–177.

52. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review and meta-analysis of the prevalence of potentially inappropriate medication use in older adults. Age Ageing. 2015;44(3):346–349.

53. Cherny NI. Palliative care: treatment of symptoms. Lancet. 2014;383:1407–1417.

54. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients. JAMA. 2005;294(6):716–724.

55. Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000;284(19):2476–2482.

56. Parshall MB, Schwartzstein RM, Adams L, et al. An official ATS statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452.

57. Johnson MJ, Currow DC. Opioids for breathlessness: a narrative review. BMJ Support Palliat Care. 2020;10(3):287–295.

58. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327:523–528.

59. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010;137(3):674–691.

60. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497–504.

61. Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer. Cochrane Database Syst Rev. 2008;(2):CD004769.

62. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2023 Report.

63. Barnes PJ. The pharmacological properties of long-acting β2-adrenoceptor agonists. Eur Respir J. 1995;8(9):1527–1533.

64. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533(1–3):2–14.

65. Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356:1862–1869.

66. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;(10):CD007354.

67. Morice AH, McGarvey L, Pavord I. Recommendations for the management of cough in adults. Thorax. 2006;61(Suppl 1):i1–i24.

68. Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177.

69. Twycross R, Wilcock A. Symptom Management in Advanced Cancer. 4th ed. Nottingham: Palliativedrugs.com; 2010.

70. Cherny NI, Radbruch L; Board of the European Association for Palliative Care. European Association for Palliative Care recommendations for the use of palliative sedation. Lancet Oncol. 2009;10(6):581–593.

71. Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–1214.

72. Fallon MT, Cherny NI, Hanks GW. Opioid analgesic therapy. In: Cherny NI, Fallon M, Kaasa S, et al., editors. Oxford Textbook of Palliative Medicine. 5th ed. Oxford: Oxford University Press; 2015.

73. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.

74. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for breathlessness and anxiety in advanced disease. Cochrane Database Syst Rev. 2016;(10):CD007354.

75. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. Lancet. 2018;391:1357–1366.

76. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;(12):CD006528.

77. Bush SH, Lawlor PG, Ryan K, et al. Delirium in adult cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv143–iv165.

78. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;(2):CD005594.

79. Girard TD, Exline MC, Carson SS, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379:2506–2516.

80. Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival. J Clin Oncol. 2012;30(12):1378–1383.

81. Dean MM, Cellarius V, Henry B, Oneschuk D, Librach SL. Framework for continuous palliative sedation therapy in Canada. J Pain Symptom Manage. 2012;44(3):431–445.

82. National Institute for Health and Care Excellence (NICE). Care of Dying Adults in the Last Days of Life. NICE Guideline NG31. London: NICE; 2015.

83. World Health Organization. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2019.

84. Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow DC, editors. Oxford Textbook of Palliative Medicine. 5th ed. Oxford: Oxford University Press; 2015.

85. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–1982.

86. Saunders C. The concept of total pain. Int J Palliat Nurs. 2001;7(7):353–355.

87. World Health Organization. Cancer Pain Relief. 2nd ed. Geneva: WHO; 1996.

88. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for the International Classification of Diseases (ICD-11). Pain. 2015;156(6):1003–1007.

89. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003;102(1–2):1–8.

90. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–S15.

91. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–284.

92. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926.

93. Van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer. Ann Oncol. 2007;18(9):1437–1449.

94. Bennett MI. Mechanisms and clinical management of cancer pain. BMJ. 2011;342:d1990.

95. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–176.

96. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1–2):1–18.

97. Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol. 2012;23(Suppl 7):vii139–vii154.

98. Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989;249:256–264.

99. Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults. J Pain Symptom Manage. 2011;41(6):1073–1093.

100. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain. Arthritis Care Res. 2011;63(Suppl 11):S240–S252.

101. Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001;344(5):363–370.

102. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018.

103. World Health Organization. Palliative Care: Key Facts. Geneva: WHO; 2020.

104. Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow DC, editors. Oxford Textbook of Palliative Medicine. 5th ed. Oxford: Oxford University Press; 2015.

105. Smith HS. Interactions among pain and comorbid diseases. Pain Physician. 2009;12(1):111–118.

106. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24(6):425–432.

107. Hui D, Bruera E. Models of integration of oncology and palliative care. Ann Palliat Med. 2015;4(3):89–98.

108. Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(1):96–112.

109. Bausewein C, Booth S, Gysels M, Higginson IJ. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2008;(2):CD005623.

110. Higginson IJ, Evans CJ. What is the evidence that palliative care teams improve outcomes for cancer patients and their families? Cancer J. 2010;16(5):423–435.

111. Saunders C. The evolution of palliative care. Patient Educ Couns. 2000;41(1):7–13.